<br>姜黄素通过调节肠道微生物群、短链脂肪酸和 Th17/Treg 平衡来保护重症肌无力小鼠,Heliyon

当前位置： X-MOL 学术 › Heliyon › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

姜黄素通过调节肠道微生物群、短链脂肪酸和 Th17/Treg 平衡来保护重症肌无力小鼠
Heliyon ( IF 3.4 ) Pub Date : 2024-02-15 , DOI: 10.1016/j.heliyon.2024.e26030
Jing Sun ₁ , Qinfang Xie ₁ , Mengjiao Sun ₁ , Wenjing Zhang ₂ , Hongxia Wang ₁ , Ning Liu ₁ , Manxia Wang ₁

Affiliation

姜黄素作为传统药物在亚洲被广泛使用。有趣的是，姜黄素及其代谢物已被证明可以影响微生物群。然而，姜黄素对重症肌无力（MG）患者肠道微生物群的影响仍不清楚。本研究旨在探讨姜黄素对鱼雷乙酰胆碱受体 (T-AChR) 诱导的 MG 小鼠模型中肠道微生物群、短链脂肪酸 (SCFA) 水平、肠道通透性和 Th17/Treg 平衡的影响。结果表明，姜黄素显着缓解T-AChR诱导的MG小鼠的临床症状。姜黄素改变肠道微生物群组成，增加微生物多样性，特别是降低 T-AChR 诱导的肠道菌群失调中产生内毒素的变形菌和脱硫弧菌水平。此外，我们发现姜黄素显着增加 T-AChR 诱导的肠道菌群失调小鼠的粪便丁酸盐水平。在姜黄素处理组中，丁酸盐水平随着产生丁酸盐的物种（例如颤螺菌、阿克曼氏菌和异杆菌）的增加而增加。此外，姜黄素还能抑制血浆中脂多糖 (LPS)、连蛋白 (zonulin) 和 FD4 水平的升高。它增强了 T-AChR 诱导的 MG 小鼠结肠中 Occludin 的表达，表明肠道通透性显着减轻。此外，姜黄素治疗纠正了 T-AChR 诱导的 Th17/Treg 细胞失衡。总之，姜黄素可能通过调节肠道微生物群和短链脂肪酸 SCFA、改善肠道通透性以及调节 Th17/Treg 平衡来保护小鼠免受重症肌无力的影响。这项研究为姜黄素在 MG 治疗中的临床价值提供了新的见解。

"点击查看英文标题和摘要"

Curcumin protects mice with myasthenia gravis by regulating the gut microbiota, short-chain fatty acids, and the Th17/Treg balance

Curcumin is widely used as a traditional drug in Asia. Interestingly, curcumin and its metabolites have been demonstrated to influence the microbiota. However, the effect of curcumin on the gut microbiota in patients with myasthenia gravis (MG) remains unclear. This study aimed to investigate the effects of curcumin on the gut microbiota community, short-chain fatty acids (SCFAs) levels, intestinal permeability, and Th17/Treg balance in a Torpedo acetylcholine receptor (T-AChR)-induced MG mouse model. The results showed that curcumin significantly alleviated the clinical symptoms of MG mice induced by T-AChR. Curcumin modified the gut microbiota composition, increased microbial diversity, and, in particular, reduced endotoxin-producing Proteobacteria and Desulfovibrio levels in T-AChR-induced gut dysbiosis. Moreover, we found that curcumin significantly increased fecal butyrate levels in mice with T-AChR-induced gut dysbiosis. Butyrate levels increased in conjunction with the increase in butyrate-producing species such as Oscillospira, Akkermansia, and Allobaculum in the curcumin-treated group. In addition, curcumin repressed the increased levels of lipopolysaccharide (LPS), zonulin, and FD4 in plasma. It enhanced Occludin expression in the colons of MG mice induced with T-AChR, indicating dramatically alleviated gut permeability. Furthermore, curcumin treatment corrected T-AChR-induced imbalances in Th17/Treg cells. In summary, curcumin may protect mice against myasthenia gravis by modulating both the gut microbiota and SCFAs, improving gut permeability, and regulating the Th17/Treg balance. This study provides novel insights into curcumin's clinical value in MG therapy.

更新日期：2024-02-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文